Initially developed for type 2 diabetes, GLP-1RAs have demonstrated robust weight loss in randomized controlled trials and real-world settings, leading to their repositioning as cornerstone obesity treatments ( Human metabolic studies consistently show that reductions in energy intake account for most of the weight loss observed during GLP-1RA therapy, whereas increases in resting energy expenditure are modest or absent ( Beyond total weight loss, the quality of weight loss has become an increasingly important clinical concern
On the flip side, someone with a 5 mg/ml vial following a 2.5 mg/ml chart draws 10 units for their 0.25 mg dose and actually gets 0.5 mg, double what was prescribed
doi: 10.1016/j.clnu.2016.11.017 299 MalekiARahimiRMalekiS
This is especially important for those who may have difficulty absorbing nutrients due to digestive issues, certain medical conditions, or simply because of age-related changes
And more importantly, you're not necessarily doing anything wrong
,aspect=ignore)
